Roche Holding AG (ROG) has sought U.S. Food and Drug Administration approval for an experimental drug to treat a form of skin cancer, the company’s oncology head said.
The filing for vismodegib to treat advanced basal cell carcinoma was based on a study to be presented at the European Multidisciplinary Cancer Congress next week, Stefan Frings said in an interview today at Roche headquarters in Basel, Switzerland. Roche is developing the drug with Lexington, Massachusetts-based Curis Inc. (CRIS)
To contact the reporter on this story: Naomi Kresge in Basel, Switzerland, via firstname.lastname@example.org
To contact the editor responsible for this story: Phil Serafino at email@example.com.